Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies
Conclusion
Monitoring of urine protein-to-creatinine ratios with each cycle may be unnecessary due to the low prevalence of grade 3 proteinuria observed. Additionally, urine protein-to-creatinine ratios may not provide adequate assessment of proteinuria toxicity associated with bevacizumab therapy. Potential cost savings opportunities for the institution can be realized with a cost-reductive monitoring algorithm that will utilize less costly laboratory techniques for patients at high risk of developing proteinuria.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Lee, C. S., Alwan, L. M., Sun, X., McLean, K. A., Urban, R. R. Tags: Original Articles Source Type: research
More News: Cancer & Oncology